Bengaluru, India: Fibroheal Woundcare Private Limited, a pioneer in biomaterial application of Silk, advanced wound care solutions and medtech segment, has raised ₹14 crore in fresh capital to accelerate its next phase of growth, strengthen its market leadership and unlock opportunities in developed markets.

The investment round brought together a distinguished group of investors with deep expertise across healthcare, finance, and life sciences. The round witnessed participation from existing set of investors like  Dr. Naresh Bhat, one of India's top 3 gastrointestinal and endoscopic specialists in India, Mr. Joseph Thomas, Co-head First families, from India’s leading Wealth and Asset Management Company, Bharat Tandon, a silk evangelist and a pioneer from Animal health space who previously built VETCARE which formed a JV with PROVIMI and exited to CARGILL. Bharat Tandon supported the company through previous funding rounds alongside KITVEN Funds and other investors. The round also saw participation and capital infusion from Vikas K. S. and Vivek Mishra, CEO of Fibroheal.

Earlier in mid 2025, Fibroheal offered a successful secondary exit for Telama Investment,one of earliest believers and backers of Fibroheal delivering an impressive 29.6% Internal Rate of Return (IRR). Telama Investment is backed by Mr. S. Subramanian, the entrepreneur behind formerly Sutures India, now known as Healthium Medtech backed by KKR. Over the years, Fibroheal has built a strong investor ecosystem comprising KITVEN Funds, C-CAMP, BIRAC, Department of Biotechnology Govt of India,  Central Silk Board, Ministry of Textiles, IT BT & ST Department – Govt of Karnataka and many industry veterans who have consistently supported the company's growth journey. Fibroheal holds 9 granted patents and have 30+ academic collaborations 

Fibroheal reported an impressive 77% revenue growth in the first quarter of FY 2026–27 compared with the previous first quarter of financial year 2025-26. Today, Fibroheal's products are used in more than 500 hospitals across India, gaining widespread acceptance among surgeons and healthcare professionals for their innovative approach to advanced wound management and more than 150,000 patients has been treated so far with Fibroheal range of products. 

Fibroheal has also partnered with a US based company called SYLKE in February 2025 who operates in area of post-operative care and currently, there is an ongoing study happening at Johns Hopkins, Baltimore around application of Silk protein-based solutions in donor sites.

Speaking on the milestone, the company said the fresh investment will enable Fibroheal to scale faster by strengthening its commercial capabilities, expanding into global markets, and advancing its mission of transforming wound care through biomaterial innovation, regenerative segment, and strategic international collaborations. 

Dr Naresh Bhat mentioned that – I doubled down my investment in Fibroheal seeing great potential in this company considering first move advantage around silk proteins-based care in medical field and I have seen outcomes of many patient wounds healing quickly with Fibroheal silk based technology especially D Fibroheal Ag Powder and their bandages.

Mr Joseph Thomas shared that “I have backed company previously also and have seen the growth of company and firmly believes that Fibroheal is reaching the stage for exponential growth and I am glad to be one among those who are giving wings to the future ambitions of Fibroheal.

Mr Bharat Tandon, who co-founded Fibroheal along with Vivek Mishra highlighted his belief on the company, “I believe the silk as platform technology is still underserved and holds great potential considering non allergenic, non-cytotoxic, biocompatible and ease of access biomaterial. Fibroheal has done a tremendous job, and I wish this team all the best to do well and multiply the economic multiplier potential of Silk proteins in medtech and biotechnology arena. I am backing Fibroheal’s vision, clinical impact and demonstrated commercial trajectory.

Mr Vivek Mishra highlighted that “This funding positions us to strengthen our global footprint while advancing various biomaterials-based breakthrough technologies that addresses significant clinical needs. This backing is a massive validation of the amazing work our team is doing at Fibroheal and will help us in scaling our operations, regulatory readiness for global markets and go to market capabilities. With the continued backing of our esteemed investors, we are perfectly positioned to take our proudly “Made in India” technologies to the global stage, while simultaneously bringing two game changing products – Fibroplug ORC - a bioresorbable material to arrest internal bleeding post surgeries and a bone regenerative solution for infected bone injuries and infections and other complex orthopaedic recoveries and is expected to launch in FY 2027.

Investment Snapshot

• Company: Fibroheal Woundcare Private Limited
• Funding Raised: ₹14 crore
• Key Investors: Dr. Naresh Bhat, Joseph Thomas (360 ONE Asset Management), Bharat Tandon, Vikas K. S., and Vivek Mishra
• Focus Areas: Commercial expansion, scaling operations, market leadership, and entry in developed markets.

With robust revenue growth, increasing adoption across leading hospitals, silk protein-based solutions being well accepted and fresh capital by existing investors to support its expansion strategy, Fibroheal is well positioned to emerge as one of India's leading medtech innovators with a growing global presence with commercial success.